53 recruiting, 49 not yet recruiting, 17 unknown, 2 active not recruiting. 98 Phase 2, 19 Phase 1, 5 Phase 3, 4 Not applicable, 2 Early Phase 1.
Follow Adebrelimab: new trials by email Literature Review of Adebrelimab trials Research Report on Adebrelimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer HS-10370, Adebrelimab, Cisplatin - Carcinoma, Non-Small-Cell Lung | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 448 | 2026-10-31 | 2026-09-16 |
| A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC Adebrelimab (SHR-1316) + chemotherapy, Adebrelimab - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Not yet recruiting | West China Hospital | 1088 | 2026-10-31 | 2026-10-26 |
| An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer. adebrelimab + SHR-A2009, paclitaxel or pemetrexed combined with carboplatin +adebrelimab, adebrelimab - Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 660 | 2026-10-30 | 2026-10-07 |
| Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC Adebrelimab, Adjuvant treatment - Lung Neoplasm Malignant | Phase 2 | Not yet recruiting | Ruijin Hospital | 64 | 2026-10-20 | 2026-10-22 |
| Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma Adebrelimab, Temozolomide, Procedure:Hyperbaric Oxygen Therapy - Glioblastoma | Phase 2 | Not yet recruiting | Wei Jiang | 94 | 2026-10-01 | 2026-08-27 |
| Perioperative Adebrelimab for Locally Advanced Cervical Cancer Adebrelimab, Paclitaxel, Cisplatin - Locally Advanced Cervical Cancer | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 35 | 2026-10-01 | 2026-09-10 |
| Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer Trastuzumab Rezetecan, Adebrelimab, Concurrent Bladder Radiotherapy - Muscle-Invasive Bladder Cancer (MIBC) | Phase 2 | Not yet recruiting | Tongji Hospital | 70 | 2026-09-01 | 2026-10-08 |
| Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab, Trastuzumab Rezetecan (SHR-A1811), Adebrelimab - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Ming Chen | 105 | 2026-09-01 | 2026-09-23 |
| Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer Adebrelimab (PD-L1 inhibitor), NALIRIFOX, SBRT - Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 36 | 2026-09-01 | 2026-09-18 |
| Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer Adebrelimab, Thymalfasin, Chemotherapy - Esophageal Cancer | Phase 2 | Not yet recruiting | The Affiliated Hospital of Putian University | 31 | 2026-08-30 | 2026-08-21 |
| A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLC Adebrelimab, Trastuzumab rezetecan - NSCLC | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 37 | 2026-08-20 | 2026-08-21 |
| A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer HRS-2329 Tablet, Nimotuzumab, HS-20093 - Pancreatic Cancer, RAS Mutations or Amplifications | Phase 1 / Phase 2 | Not yet recruiting | Zhejiang University | 80 | 2026-08-15 | 2026-08-31 |
| Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial Adebrelimab - Cervical Neoplasms | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 35 | 2026-08-01 | 2026-07-28 |
| Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC Adebrelimab, Nab paclitaxel, Carboplatin - Esophageal Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 120 | 2026-07-31 | 2026-07-29 |
| Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer Etoposide, Cisplatin, Carboplatin - Lung, Radiotherapy | Phase 2 | Recruiting | Jiangmen Central Hospital | 43 | 2026-07-20 | 2026-09-22 |
| Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer Propranolol Hydrochloride, Adebrelimab, Chemotherapy - Small Cell Lung Cancer (SCLC) | Phase 1 | Recruiting | Second Xiangya Hospital of Central South University | 18 | 2026-05-29 | 2026-10-21 |
| Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC Adebrelimab, radiotherapy - Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Chen Chunyan | 36 | 2026-05-01 | 2026-04-28 |
| Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer Trastuzumab Rezetecan, Adebrelimab, Lenvatinib - Biliary Tract Neoplasms Immunotherapy | Phase 2 | Recruiting | Peking Union Medical College Hospital | 70 | 2026-04-29 | 2026-06-26 |
| Adebrelimab Plus S-1 for Resected Cholangiocarcinoma Adebrelimab, S-1 - Cholangiocarcinoma, Biliary Tract Cancer | Phase 2 | Not yet recruiting | Xingjun Guo | 40 | 2026-04-21 | 2026-05-01 |
| Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer Trastuzumab Rezetecan, Adebrelimab, Lenvatinib - Biliary Tract Neoplasms Immunotherapy | Phase 2 | Recruiting | Peking Union Medical College Hospital | 70 | 2026-04-15 | 2026-07-15 |
Showing 20 of 122. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (13) · Small Cell Lung Carcinoma (10) · Biliary Tract Neoplasms (7) · Cholangiocarcinoma (7) · Esophageal Squamous Cell Carcinoma (6) · Pancreatic Neoplasms (6) · Carcinoma, Hepatocellular (5) · Stomach Neoplasms (5) · Colorectal Neoplasms (4) · Breast Neoplasms (3) · Esophageal Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Cirrhosis, Familial, with Pulmonary Hypertension (2) · Lung Neoplasms (2) · Nasopharyngeal Carcinoma (2)
Fudan University (9) · The First Affiliated Hospital with Nanjing Medical University (7) · Tianjin Medical University Cancer Institute and Hospital (7) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (6) · Fujian Cancer Hospital (4) · Harbin Medical University (4) · Hansoh BioMedical R&D Company (3) · Henan Cancer Hospital (3) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (3) · Peking Union Medical College Hospital (3) · Shanghai Hengrui Pharmaceutical Co., Ltd. (3) · Sun Yat-sen University (3) · Tongji Hospital (3) · West China Hospital (3) · Ningbo Medical Center Lihuili Hospital (2)
China (92)
Bo Liu, Professor (1) · Changqing Jing, Professor (1) · Chong Deng (1) · Chunyan Chen (1) · Da Chen, MD&PhD (1) · Dezhi Li, MD&PhD (1) · Fang Liu, MD (1) · Feng Cheng, MD (1) · Guangyuan Hu, Doctor (1) · Guoqin Qiu (1) · Guoxiang Cai, Doctor (1) · Hao Xu, Ph.D (1) · Hecheng Li, MD, PhD (1) · Hongxia Wang (1) · Hongxia Wang, Chief physician (1)
PMID 29366520, PMID 32716739, PMID 36434949, PMID 36529152, PMID 37011232, PMID 39252865, PMID 41730557, PMID 41816563